2019
DOI: 10.1016/j.jaad.2018.04.035
|View full text |Cite
|
Sign up to set email alerts
|

Analysis of national skin cancer expenditures in the United States Medicare population, 2013

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
18
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 20 publications
(19 citation statements)
references
References 3 publications
0
18
1
Order By: Relevance
“…To the Editor: Studies have suggested that patients with psoriasis have a higher risk of hospitalization for acute infections. [1][2][3][4] However, the impact of psoriasis on milder cases of infection treated in outpatient settings is unknown. We aimed to examine the association of psoriasis with the risk of acute infection including inpatient, outpatient, and emergency department visits and whether the risk of acute infection was associated with systemic antipsoriatic treatment using a large national cohort.…”
Section: Risk Of Acute Infections In Patients With Psoriasis: a Natiomentioning
confidence: 99%
See 1 more Smart Citation
“…To the Editor: Studies have suggested that patients with psoriasis have a higher risk of hospitalization for acute infections. [1][2][3][4] However, the impact of psoriasis on milder cases of infection treated in outpatient settings is unknown. We aimed to examine the association of psoriasis with the risk of acute infection including inpatient, outpatient, and emergency department visits and whether the risk of acute infection was associated with systemic antipsoriatic treatment using a large national cohort.…”
Section: Risk Of Acute Infections In Patients With Psoriasis: a Natiomentioning
confidence: 99%
“…1 In 2013, the annualized per-patient Medicare spending for ipilimumab was more than $80,000, whereas lifetime treatment with alternative therapies was less than $50,000. 2,3 After ipilimumab was approved and through 2015, other costly immunotherapies (programmed cell death protein 1 inhibitors) and targeted therapies (BRAF and MEK inhibitors) were approved. This cross-sectional analysis evaluates Medicare spending, out-of-pocket costs (OOPC), and utilization trends for immunotherapy, targeted therapy, and other melanoma treatments in 2013 and 2015, before the standard use of dual biologic regimens.…”
mentioning
confidence: 99%
“…UV-induced skin cancer is another outcome of chronic UV exposure associated with 90% of cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) cases and 65% of cutaneous melanoma cases (Kim and He, 2014;Linos et al, 2009). In total, they account for 3.5 million new cancer cases, nearly 15,000 deaths, and over $3 billion of medical costs annually in the United States, posing a major public health issue and economic burden (Rogers et al, 2015;Ruiz et al, 2019).…”
Section: Introductionmentioning
confidence: 99%
“…According to the statistics reported by the American skin cancer society [4], melanoma is the 19 th most commonly found problem worldwide, and 100,350 new cases of melanoma were anticipated in the USA, 16221 in Australia, and 2500 in New Zealand in 2020 [5]. In terms of pricing, it has been estimated that the cost of treating skin cancer is 3.3 billion per year [6,7]; thus, it is the most expensive procedure for the health systems.…”
Section: Introductionmentioning
confidence: 99%